Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasm Metastasis 2Melanoma 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Uterine Cervical Neoplasms 1Solid Tumors Refractory to Standard Therapy 1Solid Tumors 1Solid Tumor, Adult 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Kidney Neoplasms 1Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1ER+ HER2- Advanced Breast Cancer 1

Interventions

pembrolizumab 91Carboplatin 73Pemetrexed 58Nivolumab 50Docetaxel 47Cisplatin 47Paclitaxel 46Erlotinib Hydrochloride 37Radiotherapy 30Gemcitabine 27osimertinib 23Cetuximab 23Bevacizumab 21Ipilimumab 18Radiosurgery 14130-nm albumin-bound paclitaxel 14Taxes 13Gefitinib 13Cyclophosphamide 13avelumab 12atezolizumab 12durvalumab 11Albumin-Bound Paclitaxel 11cemiplimab 9Radiation 8Drug Therapy 8alectinib 7Injections 7Etoposide 7trametinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Carcinoma, Non-Small-Cell Lung × palbociclib × Clear all
NCT03386929 2023-12-18

SPRING

Worldwide Innovative Network Association

Phase 1/2 Terminated
15 enrolled 10 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02349633 2021-06-10

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Pfizer

Phase 1/2 Terminated
65 enrolled 61 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡